中国肺癌杂志最新文献

筛选
英文 中文
[Research Progress on the Relationship between Intratumor Microbiota and Lung Cancer]. [肿瘤内微生物群与肺癌关系的研究进展]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.101.05
Yangtong Zhu, Jiawei Chen, Yanqian Zhu, Linyu Wu
{"title":"[Research Progress on the Relationship between Intratumor Microbiota and Lung Cancer].","authors":"Yangtong Zhu, Jiawei Chen, Yanqian Zhu, Linyu Wu","doi":"10.3779/j.issn.1009-3419.2025.101.05","DOIUrl":"10.3779/j.issn.1009-3419.2025.101.05","url":null,"abstract":"<p><p>Lung cancer has the highest incidence and mortality of any cancer in the world. In recent years, with the development of microbial detection technology, the intratumor microbiota has gradually become a hot spot and frontier in the field of lung cancer research. Studies have found that the microbiota present in tumors can influence the development of lung cancer in a variety of ways. In addition, the intratumor microbiota can be used as a potential biomarker for the diagnosis and prognosis assessment of lung cancer, and the regulation of the intratumor microbiota of lung cancer is expected to become a new type of lung cancer treatment. In this paper, we reviewed the latest research progress on the relationship between intratumor microbiota and lung cancer, summarized the origin and characteristics of intratumor microbiota, discussed the mechanism of its influence on the occurrence and development of lung cancer, and explored its potential applications in the diagnosis, treatment and prognosis of lung cancer.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"304-308"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Prospective Cohort Study on Soy Product Intake and the Risk of Lung Cancer 
Based on Shanghai Suburban Adult Cohort and Biobank]. [基于上海郊区成人队列和生物库的豆制品摄入与肺癌风险的前瞻性队列研究
]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.106.09
Shiyun Ding, Wenhui Wu, Jianing Mao, Jingrao Li, Ji Zheng, Ye Yao, Genming Zhao, Yiling Wu, Ruoxin Zhang
{"title":"[A Prospective Cohort Study on Soy Product Intake and the Risk of Lung Cancer \u2029Based on Shanghai Suburban Adult Cohort and Biobank].","authors":"Shiyun Ding, Wenhui Wu, Jianing Mao, Jingrao Li, Ji Zheng, Ye Yao, Genming Zhao, Yiling Wu, Ruoxin Zhang","doi":"10.3779/j.issn.1009-3419.2025.106.09","DOIUrl":"10.3779/j.issn.1009-3419.2025.106.09","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Lung cancer is one of the malignant cancers with the highest incidence rate, and it is important to identify the factors contributing to lung cancer carcinogenesis for prevention. Lifestyle and genetic factors play important roles in cancer development, however the impact of dietary factors, such as soy product intake, on lung cancer risk remains inadequately understood. This study aims to explore the associations between soy product intake, genetic risk, and lung cancer incidence, and validate the consistent effects of soy product intake in European populations, thereby providing new insights for lung cancer prevention.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Utilizing the Shanghai Suburban Adult Cohort and Biobank (SSACB) (n=66,311), Cox proportional hazards model was adopted to assess the association between soy product intake and lung cancer incidents, followed by subgroup analyses stratified by gender, smoking status, and pathological types of lung cancer. The UK Biobank (UKB) was used for validation of the effect of soy product intake on lung cancer. To investigate the association between genetic factors and lung cancer, in addition to previously reported loci, we incorporated newly identified loci from two independent studies in Southeast China: a nested case-control population from the SSACB cohort (433 cases/650 controls) and a case-control study from the Shanghai Cancer Center-Taizhou cohort (1359 cases/1359 controls). Meta-analysis and Linkage disequilibrium clumping (LD clumping) of the association results identified 23 loci for polygenic risk score (PRS) construction. Subsequently, conditional Logistic regression model was used to assess the association between genetic risk and lung cancer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In SSACB cohort, after adjusting for age, gender, smoking, chronic bronchitis, body mass index (BMI), vegetable intake and red meat intake, sufficient soy product intake was significantly associated with a reduced risk of lung cancer [hazard ratio (HR)=0.60, 95%CI: 0.47-0.77, Padj=6.69E-05], an effect that was consistent in males and females, smokers and non-smokers. In UKB, although the association did not reach statistical significance, a protective trend against lung cancer was also observed (HR=0.76, 95%CI: 0.55-1.06, Padj=0.10). In the nested case-control population within SSACB, a PRS score generated in the Chinese population was significantly correlated with lung cancer risk. After adjustment of age, gender, smoking, chronic bronchitis, and soy product intake, the high-PRS group had a 1.88 times higher risk of lung cancer compared to the low-PRS group (Padj=1.84E-03).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The prospective cohort study found that adequate intake of soy products was significantly associated with a reduced risk of lung cancer, while a high PRS is a risk factor for lung cancer development. Integrating soy product intake and PRS into traditional epidemiological risk factor pre","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"291-303"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Public Database-based Study to Explore the Expression and Role of DDB1 
in Lung Adenocarcinoma]. [基于公共数据库的研究探讨DDB1
在肺腺癌中的表达及其作用]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.102.12
Xinkai Zou, Ziyi He, Yanfei Zhang, Yi Hu, Xiaomin Wang, Zhongjie Wu
{"title":"[Public Database-based Study to Explore the Expression and Role of DDB1 \u2029in Lung Adenocarcinoma].","authors":"Xinkai Zou, Ziyi He, Yanfei Zhang, Yi Hu, Xiaomin Wang, Zhongjie Wu","doi":"10.3779/j.issn.1009-3419.2025.102.12","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.12","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) is the predominant subtype of non-small cell lung cancer (NSCLC). Damage-specific DNA binding protein 1 (DDB1), as a core protein of the CUL4-DDB1 ubiquitin ligase complex, is involved in the regulation of DNA damage repair, epigenetic modification, and cell cycle checkpoint activation. While the involvement of DDB1 in tumour progression through DNA repair and RNA transcriptional regulation has been reported, its expression and role in LUAD remain to be elucidated. This study aims to investigate the expression and role of DDB1 in LUAD.</p><p><strong>Methods: </strong>The expression, clinicopathological features and prognosis of DDB1 in LUAD were analysed using databases such as UALCAN, Kaplan-Meier Plotter and GEPIA; The interaction network and enriched functional pathways were constructed by GeneMANIA and Metascape; the correlation between DDB1 and immune cells by combining with TISIDB infiltration was evaluated, and the clustering results of cell subtypes and the expression of DDB1 in different immune cell subpopulations were analysed by single-cell sequencing; finally, tissue microarrays were used to further verify the expression and prognostic value of DDB1 in LUAD.</p><p><strong>Results: </strong>The mRNA and protein expression of DDB1 in LUAD tissues were significantly higher than those in normal tissues (P<0.01), and the high expression correlated with later clinical stage (P<0.001), lymph node metastasis (P<0.001) and poor prognosis (P<0.001). Functional enrichment showed that DDB1 was involved in DNA repair and RNA transcriptional regulation, and TISIDB evaluation revealed that DDB1 was negatively correlated with the expression level of immune cells, suggesting the potential regulation of the immune microenvironment. Single cell analysis showed that DDB1 was mainly expressed in T cells, alveolar macrophages and dendritic cells. Tissue microarrays confirmed that overall survival was shorter in the DDB1 high expression group (P<0.001), and Cox multifactorial analysis showed that DDB1 was an independent predictor of LUAD prognosis.</p><p><strong>Conclusions: </strong>DDB1 is highly expressed in LUAD, which is associated with poor prognosis, and is closely related to tumor immune cell infiltration, and is involved in tumourigenesis and development through DNA repair and RNA transcriptional regulation. DDB1 can be used as a potential prognostic marker and therapeutic target for LUAD.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"256-266"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research Progress and Applications of ZDHHC-mediated Protein Palmitoylation 
in the Development and Immune Escape of Non-small Cell Lung Cancer]. [zdhhc介导的蛋白棕榈酰化
在非小细胞肺癌发生和免疫逃逸中的研究进展及应用]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.102.15
Wangcheng Chen, Lili Pang, Yuemei Lan, Yanhong Shi, Bingbing Wen, Baihong Zhang
{"title":"[Research Progress and Applications of ZDHHC-mediated Protein Palmitoylation \u2029in the Development and Immune Escape of Non-small Cell Lung Cancer].","authors":"Wangcheng Chen, Lili Pang, Yuemei Lan, Yanhong Shi, Bingbing Wen, Baihong Zhang","doi":"10.3779/j.issn.1009-3419.2025.102.15","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.15","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC), a leading cause of cancer-related deaths worldwide, remains a significant clinical challenge despite advances in immune checkpoint inhibitors therapy, with drug resistance persisting as a major obstacle. Palmitoylation, a critical post-translational modification (PTM) primarily catalyzed by palmitoyltransferases of the zinc finger DHHC-type (ZDHHC), has recently demonstrated important implications in NSCLC. This review aims to elucidate the mechanisms and clinical potential of ZDHHC-mediated protein palmitoylation in NSCLC progression and immune escape.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"319-324"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Application Value of an AI-based Imaging Feature Parameter Model 
for Predicting the Malignancy of Part-solid Pulmonary Nodule]. [基于人工智能的影像特征参数模型
在预测部分实性肺结节恶性程度中的应用价值]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.102.13
Mingzhi Lin, Yiming Hui, Bin Li, Peilin Zhao, Zhizhong Zheng, Zhuowen Yang, Zhipeng Su, Yuqi Meng, Tieniu Song
{"title":"[Application Value of an AI-based Imaging Feature Parameter Model \u2029for Predicting the Malignancy of Part-solid Pulmonary Nodule].","authors":"Mingzhi Lin, Yiming Hui, Bin Li, Peilin Zhao, Zhizhong Zheng, Zhuowen Yang, Zhipeng Su, Yuqi Meng, Tieniu Song","doi":"10.3779/j.issn.1009-3419.2025.102.13","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.13","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is one of the most common malignant tumors worldwide and a major cause of cancer-related deaths. Early-stage lung cancer is often manifested as pulmonary nodules, and accurate assessment of the malignancy risk is crucial for prolonging survival and avoiding overtreatment. This study aims to construct a model based on image feature parameters automatically extracted by artificial intelligence (AI) to evaluate its effectiveness in predicting the malignancy of part-solid nodule (PSN).</p><p><strong>Methods: </strong>This retrospective study analyzed 229 PSN from 222 patients who underwent pulmonary nodule resection at Lanzhou University Second Hospital between October 2020 and February 2025. According to pathological results, 45 cases of benign lesions and precursor glandular lesion were categorized into the non-malignant group, and 184 cases of pulmonary malignancies were categorized into the malignant group. All patients underwent preoperative chest computed tomography (CT), and AI software was used to extract imaging feature parameters. Univariate analysis was used to screen significant variables; variance inflation factor (VIF) was calculated to exclude highly collinear variables, and LASSO regression was further applied to identify key features. Multivariate Logistic regression was used to determine independent risk factors. Based on the selected variables, five models were constructed: Logistic regression, random forest, XGBoost, LightGBM, and support vector machine (SVM). Receiver operating characteristic (ROC) curves were used to assess the performance of the models.</p><p><strong>Results: </strong>The independent risk factors for the malignancy of PSN include roughness (ngtdm), dependence variance (gldm), and short run low gray-level emphasis (glrlm). Logistic regression achieved area under the curves ( AUCs) of 0.86 and 0.89 in the training and testing sets, respectively, showing good performance. XGBoost had AUCs of 0.78 and 0.77, respectively, demonstrating relatively balanced performance, but with lower accuracy. SVM showed an AUC of 0.93 in the training set, which decreased to 0.80 in the testing set, indicating overfitting. LightGBM performed excellently in the training set with an AUC of 0.94, but its performance declined in the testing set, with an AUC of 0.88. In contrast, random forest demonstrated stable performance in both the training and testing sets, with AUCs of 0.89 and 0.91, respectively, exhibiting high stability and excellent generalizability.</p><p><strong>Conclusions: </strong>The random forest model constructed based on independent risk factors demonstrated the best performance in predicting the malignancy of PSN and could provide effective auxiliary predictions for clinicians, supporting individualized treatment decisions.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"281-290"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Analysis of Risk Factors for Meningeal Metastasis in Patients 
with Lung Adenocarcinoma Following Non-surgical Interventions]. [肺腺癌非手术干预后
患者脑膜转移的危险因素分析]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.101.06
Yi Yue, Yuqing Ren, Jianlong Lin, Chunya Lu, Nan Jiang, Yanping Su, Jing Li, Yibo Wang, Sihui Wang, Junkai Fu, Mengrui Kong, Guojun Zhang
{"title":"[Analysis of Risk Factors for Meningeal Metastasis in Patients \u2029with Lung Adenocarcinoma Following Non-surgical Interventions].","authors":"Yi Yue, Yuqing Ren, Jianlong Lin, Chunya Lu, Nan Jiang, Yanping Su, Jing Li, Yibo Wang, Sihui Wang, Junkai Fu, Mengrui Kong, Guojun Zhang","doi":"10.3779/j.issn.1009-3419.2025.101.06","DOIUrl":"10.3779/j.issn.1009-3419.2025.101.06","url":null,"abstract":"<p><strong>Background: </strong>Meningeal metastasis (MM) is a form of malignant metastasis where tumor cells spread from the primary site to the pia mater, dura mater, arachnoid, subarachnoid space, and other cerebrospinal fluid compartments. Lung cancer is one of the most common malignant tumor types with MM. MM not only signifies that the lung cancer has progressed to an advanced stage but also leads to a range of severe clinical symptoms due to meningeal involvement. Currently, the risk factors associated with the development of MM are not fully elucidated. The aim of this study was to investigate the risk factors for MM in patients with lung adenocarcinoma (LUAD) who underwent non-surgical interventions, in order to identify LUAD patients at high risk for MM.</p><p><strong>Methods: </strong>This retrospective study analyzed the clinical data of patients diagnosed with LUAD at the First Affiliated Hospital of Zhengzhou University from January 2020 to July 2024. Missing data were imputed using multiple imputation methods, and risk factors were identified through LASSO, univariate, and multivariate Logistic regression analyses.</p><p><strong>Results: </strong>A total of 170 patients with LUAD were included in this study and divided into two groups: 87 patients with MM and 83 patients without MM. Univariate and multivariate Logistic regression analyses revealed that younger age at diagnosis (P=0.004), presence of the epidermal growth factor receptor (EGFR) L858R gene mutation (P=0.008), and concurrent liver metastasis at baseline (P=0.004) were independent risk factors for developing MM in LUAD patients who did not undergo surgical intervention. Conversely, higher baseline globulin levels (P=0.039) and the presence of the anaplastic lymphoma kinase (ALK) gene mutation (P=0.040) were associated with a reduced risk of MM development.</p><p><strong>Conclusions: </strong>Age at diagnosis, EGFR L858R mutation status, ALK gene mutation status, concurrent liver metastasis, globulin levels at baseline were significantly associated with the risk of developing MM in patients with LUAD patients who did not undergo surgical intervention. For patients diagnosed at a younger age, carrying the EGFR L858R mutation, or presenting with baseline liver metastasis, early implementation of tertiary prevention strategies for MM is crucial. Regular monitoring of MM status should be conducted in these high-risk groups.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"267-280"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research Progress of Anti-lung Cancer Drug-related Interstitial Lung Disease]. [抗肺癌药物相关性间质性肺疾病研究进展]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.106.11
Zhimin Xiao, Yan Gu
{"title":"[Research Progress of Anti-lung Cancer Drug-related Interstitial Lung Disease].","authors":"Zhimin Xiao, Yan Gu","doi":"10.3779/j.issn.1009-3419.2025.106.11","DOIUrl":"10.3779/j.issn.1009-3419.2025.106.11","url":null,"abstract":"<p><p>Lung cancer is the cancer with the highest incidence and mortality rate worldwide. In addition to the diversified treatment and prolonged lifespan in view of the development of medical technology, the side effect of medicine should not be ignored. Drug-induced interstitial lung disease (DI-ILD) is also commonly encountered during this process, and ILD triggered by the treatment of lung cancer characterized by the inflammation and scarring of lung tissue after the antitumor treatment in lung cancer leads to a poor prognosis and high mortality. The diagnosis and treatment of ILD caused by anti-lung cancer agents remains challenging in clinical settings and requires joint efforts from multidisciplinary team (MDT). This review systematically updates the epidemiology, molecular pathogenesis, genomics/genetics study, diagnosis and treatment of ILD related to anti-lung cancer agents. By the integration of the latest evidences, the paper offers clinical work references for early diagnosis of ILD related to anti-lung cancer agents to enhance the survival and quality of life of the lung cancer patients.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"309-318"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Expert Consensus on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer]. [肺癌小分子靶向药物合理使用与监测专家共识]。
中国肺癌杂志 Pub Date : 2025-04-20 DOI: 10.3779/j.issn.1009-3419.2025.106.10
Liyan Zhao, Kejing Tang
{"title":"[Expert Consensus on Rational Use and Monitoring of Small Molecule Targeted Drugs for Lung Cancer].","authors":"Liyan Zhao, Kejing Tang","doi":"10.3779/j.issn.1009-3419.2025.106.10","DOIUrl":"10.3779/j.issn.1009-3419.2025.106.10","url":null,"abstract":"<p><p>The application of small molecule targeted drugs for lung cancer has significantly improved the survival of lung cancer patients. However, these drugs have a wide variety of types, fast development and market launch of new drugs, complex adverse reactions, and are mostly used at home, which increases the risk of irrational drug use. At the same time, insufficient monitoring of efficacy and safety is also prone to occur, ultimately affecting treatment outcomes. This consensus focuses on 43 small molecule targeted drugs or combinations for lung cancer, providing standardized recommendations for rational drug use and monitoring of efficacy/adverse reactions in clinical practice. The recommendations are regarding drug selection, dosage adjustment, efficacy monitoring, adverse reaction monitoring, and improvement of patient compliance. This consensus aims to improve the rational use and efficacy/safety monitoring quality of small molecule targeted drugs for lung cancer, ensure the effectiveness and safety of drug treatment, prolong the survival of lung cancer patients and improve their quality of life.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 4","pages":"245-255"},"PeriodicalIF":0.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research Advances in Targeting the YAP/TAZ Signaling Pathway 
to Improve Cancer Immunotherapy]. [靶向YAP/TAZ信号通路
改善癌症免疫治疗的研究进展]。
中国肺癌杂志 Pub Date : 2025-03-20 DOI: 10.3779/j.issn.1009-3419.2025.102.08
Pingxu Zhang, Yiyi Zhan
{"title":"[Research Advances in Targeting the YAP/TAZ Signaling Pathway \u2029to Improve Cancer Immunotherapy].","authors":"Pingxu Zhang, Yiyi Zhan","doi":"10.3779/j.issn.1009-3419.2025.102.08","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2025.102.08","url":null,"abstract":"<p><p>Despite the groundbreaking advances in cancer immunotherapy achieved by immune checkpoint inhibitors (ICIs), their efficacy remains limited by the immunosuppressive tumor microenvironment (TME). Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), key effectors of the Hippo signaling pathway, play pivotal roles in tumor immune evasion. They directly regulate the expression of immune checkpoints, mediate the formation of an immunosuppressive microenvironment, inhibit T cell function, and interact with other signaling pathways to promote immune escape. Diverse strategies targeting YAP/TAZ have been developed, including direct inhibition, modulation of upstream regulators, and suppression of downstream target genes. Preclinical studies have demonstrated that combining YAP/TAZ inhibition with ICIs significantly enhances therapeutic efficacy across various tumor models. This review summarizes recent advances in understanding the role of YAP/TAZ in immune evasion within the TME and explores the potential of targeting this pathway to improve immunotherapy outcomes. Furthermore, it discusses the translational value of combination therapies based on YAP/TAZ inhibition, providing a theoretical framework and practical guidance for the development of innovative immunotherapeutic strategies and precision medicine approaches.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 3","pages":"221-229"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Brain and Meningeal Metastases of Lung Cancer Manifested as Brain Calcifications: 
A Case Report and Literature Review]. [肺癌脑及脑膜转移表现为脑钙化:
1例报告及文献复习]。
中国肺癌杂志 Pub Date : 2025-03-20 DOI: 10.3779/j.issn.1009-3419.2025.106.05
Deng Zhang, Yiru Kong, Xiaohua Liang, Xinli Zhou
{"title":"[Brain and Meningeal Metastases of Lung Cancer Manifested as Brain Calcifications: \u2029A Case Report and Literature Review].","authors":"Deng Zhang, Yiru Kong, Xiaohua Liang, Xinli Zhou","doi":"10.3779/j.issn.1009-3419.2025.106.05","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2025.106.05","url":null,"abstract":"<p><p>Lung cancer is still one of the most common malignant tumors in the world. With the increase of its incidence and the development of medical technology, the overall survival of lung cancer patients has significantly extended compared to before. The incidence of brain and meningeal metastases from lung cancer has also been rising year by year, but patients with brain and meningeal metastases from lung cancer have a poor prognosis and a very high mortality rate, and the diagnosis is mainly based on computed tomography (CT), magnetic resonance imaging (MRI) and other imaging examinations. However, the imaging features are diverse and the specificity is low, which makes it easy to be misdiagnosed and missed. Therefore, accurately identifying brain and meningeal metastases and timely targeted treatment is crucial for improving patient prognosis. This paper analyzed the diagnosis and treatment of a case of lung cancer with no obvious recurrence and metastasis in nearly 7-year long-term follow-up after radical lung cancer surgery, but the patient with abnormal behavior, impaired consciousness and epilepsy in the past 5 months, and multiple punctate calcifications in the brain found by head CT and MRI. This paper consider that the patient's mental and behavioral symptoms were caused by brain and meningeal metastasis of lung cancer after excluding infectious disease and ineffective treatment of autoimmune encephalitis, and further pathological biopsy and genetic detection confirmed the diagnosis of metastatic lung adenocarcinoma with epidermal growth factor receptor (EGFR) L858R gene mutation, and the patient's symptoms were significantly improved after targeted therapy by Osimertinib. This paper also searched the relevant literatures of brain calcifications in databases such as China National Knowledge Infrastructure (CNKI), Wanfang, UpToDate, PubMed, etc., and found that intracerebral calcifications exist in a variety of diseases, including infectious, genetic and neurodegenerative diseases, vascular diseases, metabolic diseases and tumors. However, brain calcification in brain and meningeal metastases are often underestimated, and the consequent risk is misdiagnosis and delayed treatment. Therefore, brain and meningeal metastases manifested as brain calcification should not be ignored in patients with a history of previous tumors.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 3","pages":"237-244"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信